What bacteria are susceptible to Nitrofurantoin (antibiotic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bacteria Susceptible to Nitrofurantoin

Nitrofurantoin is highly effective against most common uropathogens, particularly Escherichia coli, Staphylococcus saprophyticus, and Enterococcus species, including vancomycin-resistant enterococci (VRE). 1, 2

Primary Susceptible Organisms

  • Escherichia coli: Maintains excellent susceptibility despite increasing resistance to other antibiotics. E. coli remains highly susceptible to nitrofurantoin even when resistant to fluoroquinolones and trimethoprim-sulfamethoxazole 1, 3
  • Staphylococcus saprophyticus: Highly susceptible with significant killing effect 3
  • Enterococcus species: Including E. faecalis and E. faecium 4, 5
  • Vancomycin-resistant enterococci (VRE): Notably, nitrofurantoin maintains activity against VRE, making it valuable for resistant infections 1, 4

Susceptibility Patterns

  • Studies show 88% of Enterococcus isolates are susceptible to nitrofurantoin 5
  • Among strains resistant to other antibiotics (ampicillin, co-trimoxazole, doxycycline, imipenem, and vancomycin), 50-88% remain susceptible to nitrofurantoin 5
  • No resistance was found in 300 tested isolates of E. faecium, E. faecalis, and E. gallinarum, including vancomycin-resistant strains 4

Pharmacodynamic Properties

  • Nitrofurantoin exhibits concentration-dependent bactericidal activity against E. coli 3
  • The time above MIC (T>MIC) correlates best with antibacterial effect 3
  • Requires bacterial nitroreductases for activation, which convert it to its active form 6
  • Metabolic activity of bacteria can influence susceptibility - bacteria in stationary phase may be less susceptible unless metabolites are present 6

Clinical Applications

  • Recommended as a first-line agent for uncomplicated lower urinary tract infections by WHO and IDSA guidelines 7, 1
  • The WHO Essential Medicines list categorizes nitrofurantoin as an Access (A) category antibiotic for lower UTIs 7
  • Particularly valuable in settings with high resistance to fluoroquinolones and trimethoprim-sulfamethoxazole 2
  • Should not be used for pyelonephritis or systemic infections due to inadequate serum concentrations 1

Resistance Considerations

  • Nitrofurantoin maintains high activity against E. coli despite increasing resistance to other antibiotics 2
  • The susceptibility of E. coli to nitrofurantoin in urinary isolates remains generally high in both adults and children 7
  • Nitrofurantoin becomes more cost-effective when fluoroquinolone-resistant E. coli exceeds 12% prevalence 7

Important Limitations

  • Not effective for pyelonephritis or prostatitis due to poor tissue penetration 7, 1
  • Contraindicated in patients with renal impairment and in the last trimester of pregnancy 1, 2
  • Primarily excreted in urine, with poor tissue penetration, limiting its use to lower urinary tract infections 1

Nitrofurantoin's continued effectiveness against common uropathogens, including resistant strains, makes it a valuable option for uncomplicated urinary tract infections, particularly in an era of increasing antimicrobial resistance.

References

Guideline

Nitrofurantoin Effectiveness in Treating Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Nitrofurantoin--clinical relevance in uncomplicated urinary tract infections].

Medizinische Monatsschrift fur Pharmazeuten, 2014

Research

Pharmacodynamic studies of nitrofurantoin against common uropathogens.

The Journal of antimicrobial chemotherapy, 2015

Research

Nitrofurantoin is active against vancomycin-resistant enterococci.

Antimicrobial agents and chemotherapy, 2001

Research

In-vitro activity of nitrofurantoin in enterococcus urinary tract infection.

JPMA. The Journal of the Pakistan Medical Association, 2004

Research

Metabolites Potentiate Nitrofurans in Nongrowing Escherichia coli.

Antimicrobial agents and chemotherapy, 2021

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.